Slide 1: H1/Q2 2026 Results
H1/Q2 2026 RESULTS OLIVIER RIGAUD (CEO) PETER KAZIUS (CFO) 31-Jul-2026
Slide 2: Forward-looking statements
H1/Q2 2026 RESULTS This presentation contains forward-looking statements with respect to Corbion’s future performance and position. Such statements are based on current expectations, estimates, and projections of Corbion and information currently available to the company. Corbion cautions readers th
Slide 3: Corbion results H1/Q2 2026
H1/Q2 2026 RESULTS Corbion results H1/Q2 2026 Olivier Rigaud Peter Kazius CEO CFO • Business performance • Financial performance • Outlook 3 31/07/2026
Slide 4: Business performance
H1/Q2 2026 RESULTS Business performance Olivier Rigaud CEO 4 31/07/2025
Slide 5: H1 2026 Highlights
H1/Q2 2026 RESULTS H1 2026 Highlights Volume/mix • Organic sales growth of +2.1% to € 631.1 million (Q2: +8.5% to € 337.4 million) • Volume/mix +4.0% +4.0% (H1) • Pricing -1.9% +10.7% (Q2) • Adjusted EBITDA € 88.8 million (Q2: € 51.0 million) Adj EBITDA margin • Health & Nutrition: Double-digit-% vo
Slide 6: Functional Ingredients & Solutions
H1/Q2 2026 RESULTS Functional Ingredients & Solutions Q2 accelerates as margin recovery begins Business environment • Sales grew +3.6% in H1 and +8.4% in Q2 on higher volumes and improved sales • Markets stayed resilient; stable pricing Food wins keep momentum positive • Middle East conflict impacti
Slide 7: Health & Nutrition
H1/Q2 2026 RESULTS Health & Nutrition Tight omega-3 supply gives Nutrition a stronger H2 Business environment • Double-digit-% volume/mix growth in Nutrition and Biomaterials • Supply shortages + resilient aquaculture demand support H2 pricing in Nutrition • Q2 sales improved strongly as customer ph
Slide 8: Fish oil dynamics: Tight supply meets resilient aquaculture demand
H1/Q2 2026 RESULTS Fish oil dynamics: Tight supply meets resilient aquaculture demand Supply risk map Nordics quota constraints Supply remains fragile • Peru reduced quotas constrain availability • Nordic / Scandinavian quotas limit alternative fish oil supply Demand anchored by salmon farming • Aqu
Slide 9: Financial performance
H1/Q2 2026 RESULTS Financial performance Peter Kazius CFO 9 31/07/2026
Slide 10: H1 Sales and Adjusted EBITDA development
H1/Q2 2026 RESULTS H1 Sales and Adjusted EBITDA development Sales H1 Adjusted EBITDA H1 € million -2.2% € million -16.7% 4.8 106.6 0.0 17.9 8.5 645.6 Q1: -€ 12 million 0.0 Q2: +€ 7 million 27.6 9.3 88.8 Q1: -€ 11 million Q1: -€ 2 million 631.1 Q2: +€2 million Q2: +€ 20 million Sales FI&S H&N Acq./Di
Slide 11: Profit and Loss
H1/Q2 2026 RESULTS Profit and Loss € million YTD YTD Q2 Q2 2026 2025 % 2026 2025 % Net Sales 631.1 645.6 -2.2% 337.4 315.9 6.8% Adjusted EBITDA 88.8 106.6 -16.7% 51.0 52.2 -2.3% Adjusted Depreciation & Amortization -42.9 -42.5 0.9% -21.2 -22.1 -4.1% Adjustments -3.8 -0.6 -2.4 -0.6 EBIT 42.1 63.5 -33
Slide 12: Functional Ingredients & Solutions Q2
H1/Q2 2026 RESULTS Functional Ingredients & Solutions Q2 Organic sales growth Functional Ingredient & Solutions +8.7% H1 Organic Sales growth of +3.6% (Q2: +8.4%) • Volume/mix +4.2% (Q2: +8.7%) Food - growth in natural preservation, particularly in bakery, petfood, and seafood end- markets Bioch
Slide 13: Health & Nutrition Q2
H1/Q2 2026 RESULTS Health & Nutrition Q2 Organic sales growth Health & Nutrition +8.7% H1 Organic Sales growth of -3.3% (Q2: +8.7%) • Volume/mix +2.8% (Q2: +16.9%) Nutrition – double-digit-% volume/mix growth in H1, following strongly Q2 with as- expected phasing Biomedical Polymers – double-dig
Slide 14: TotalEnergies Corbion joint venture
H1/Q2 2026 RESULTS TotalEnergies Corbion joint venture Sales - TotalEnergies Corbion JV Q2 +44.7% H1 sales growth +21.6% (Q2: +44.7%) • Strong demand for PLA plastics, particularly in Asia H1 Adjusted EBITDA margin 7.5%, -220 bps vs LY (Q2: 9.2%, -250 bps) • Adjusted EBITDA margin higher vs Q1 Q1-25
Slide 15: Investments, working capital, and Free Cash Flow
H1/Q2 2026 RESULTS Investments, working capital, and Free Cash Flow CapEx Program Operating Working Capital Free Cash Flow (€ million) (% of sales) (€ million) – excluding divestments Thai LA plant Expansion Maintenance Accounts Receivable Inventories Accounts Payable 127.6 28.1% 98 24.9% 25.3% 24.2
Slide 16: Outlook
H1/Q2 2026 RESULTS Outlook Olivier Rigaud CEO 16 31/07/2026
Slide 17: FY 2026 outlook adjusted
H1/Q2 2026 RESULTS FY 2026 outlook adjusted Organic sales growth: +3-6% [Maintained] Adjusted EBITDA margin: >16% [Previously ~17%] Free Cash Flow*: € 85-90 million [Maintained] CapEx spend 2026-2028: ~6% of sales [Maintained] 17 31/07/2026 * Free Cash Flow = Cash Flow from operating activities -/-
Slide 18: Annex
H1/Q2 2026 RESULTS Annex 18 31/07/2026
Slide 19: Sales and Adjusted EBITDA: H1/Q2 2026
H1/Q2 2026 RESULTS Sales and Adjusted EBITDA: H1/Q2 2026 H1 H1 H1 Q2 Q2 Q2 € million 2026 2025 Growth 2026 2025 Growth Sales - Functional Ingredients & Solutions 492.7 497.5 -1.0% 256.7 240.5 +6.7% - Health & Nutrition 138.4 148.1 -6.5% 80.7 75.4 +7.0% Total Net Sales 631.1 645.6 -2.2% 337.4 315.9 +
Slide 20: Sales growth per segment in H1/Q2 2026
H1/Q2 2026 RESULTS Sales growth per segment in H1/Q2 2026 Acq./ Total Sales growth Vol./Mix Price Organic FX Div. growth H1 2026 vs H1 2025 Total +4.0% -1.9% +2.1% -4.3% 0.0% -2.2% - Functional Ingredients & Solutions +4.2% -0.6% +3.6% -4.6% 0.0% -1.0% - Health & Nutrition +2.8% -6.1% -3.3% -3.2% 0.
Slide 21: Net debt bridge H1 2026
H1/Q2 2026 RESULTS Net debt bridge H1 2026 HY1 2026 vs End-2025 481.6 € million 7.9 6.6 7.9 32.7 401.9 • Net debt position H1 2026: € 481.6 million 57.6 (incl. subordinated loans). 88.8 55.8 381.8 • Net debt/EBITDA 2.6x 302.1 • Covenant Net Debt to covenant EBITDA: 2.0x • Positive Free Cash Flow in
Slide 22: Investor relations
Investor relations alex.sokolowski@corbion.com www.corbion.com +31 20 590 6341